

# MARKET REPORT



Poly(adenosine diphosphate [ADP]-ribose)  
Polymerases (PARPs) Inhibitors Successful targeting  
of DNA Repair Pathways by PARP Inhibitors – Current  
and Future Potential

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Poly(adenosine diphosphate [ADP]-ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Poly(adenosine diphosphate [ADP]-ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential

Poly(adenosine diphosphate [ADP]-ribose) polymerases (PARPs) activity is essential for the repair of damaged DNA. The DNA repair pathway is defective/mutated in several cancers (BRCA1, BRCA2 ovarian and breast cancer, etc) and further impairing this pathway by PARP inhibitors in these cancers is the basis of developing DNA repair targeted therapies. In the Last four years three drugs targeting PARPs have been approved for Ovarian Cancer (BRCA mutant) and new clinical data supports further label expansion of this class of drugs in other solid tumors. PARP inhibitors have demonstrated clear patient benefit in germline BRCA (gBRCA), Homologous Recombination (HR)-deficient, and other ovarian cancers. The market opportunity of this class of drug in the approved Ovarian cancer indication itself is large and the best is yet to come from the label expansion in other cancers- Prostate, Breast, Lung, Endometrial, Pancreatic, Glioblastoma Multiforme (GBM), , etc. as a monotherapy or in combination with other targeted drugs. The innovator companies have pegged the market opportunity of this class of drugs beyond \$5bn which should trigger M&A activity at attractive terms for them. In this report, we highlight the rationale of inhibiting PARP in different cancers and the promising clinical data. Clinical progress of PARP inhibitors as a monotherapy against tumors with existing DNA repair defects, such as BRCA1 and BRCA2 and other mutations, and as a combination therapy when administered with other targeted therapies as well as chemotherapeutics that induce DNA damage.

## Additional Details

**Publisher :** ProGrow Pharma Partners

**Reference :** -

**Number of Pages :** 56

**Report Format :** PDF

**Publisher Information :**



**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

ProGrow  
Pharma Partners

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

## **ProGrow Pharma Partners - Company Profile**

ProGrow Pharma (PGP) Partners is an advisory firm with a team of professionals having more than a decade of experience in serving the Pharmaceutical Industry. Team @ PGP has an in-depth understanding of the science and challenges associated with innovation, drug development, clinical trials, patents & litigations and competition across geographies, and competitive landscape in specific therapy, molecular target, or diseases.

Our exclusive focus and knowledge of the Global Biotech, and Healthcare sector enables us to offer advisory services to healthcare companies (Market leaders, Innovators, Generic Players CROs and others ) and its Investors (Private Equity investors, Venture Capitalists, HNIs and others). Our research and domain knowledge support the clients in making strategic decisions to accelerate the growth of the company.

# Table Of Contents for Poly(adenosine diphosphate [ADP]-ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-0-2017]

- TABLE OF CONTENTS1. Executive Summary 42. Overview of PARP Inhibitors 63. Strategy Used in developing PARP Inhibitors as drugs – Turning Mutations against the Cancer Cells 84. Competitive Landscape – PARP inhibitors-drugs in pipeline 95. Potential of PARP Inhibitors set to Unfold! 116. PARP Inhibitors in Approved Indication- Ovarian Cancer 13• Current Treatment options in Ovarian Cancer 14• PARP Inhibitors in Ovarian Cancer 14• Clinical data and future Label Expansion in Ovarian Cancer 15• Ongoing clinical trials in Ovarian cancer 197. Breast Cancer 218. Prostate Cancer 229. Lung Cancer – Non-Small Cell Lung Cancer (NSCLC) 2310. Other Cancers 24• Pancreatic Cancer 24• Endometrial Cancer 25• Brain Tumors- GBM 25• Gastric Cancer 2611. Commercial Outlook 2712. M & A Opportunity 2913. Key Milestones 3114. Appendix I – Ovarian Cancer – Ongoing Clinical Trials 3315. Appendix II – Breast Cancer – Ongoing Clinical Trials 4016. Appendix III – Prostate Cancer – Ongoing Clinical Trials 4517. Appendix IV – Lung Cancer – Ongoing Clinical Trials 4718. Appendix V – Other Cancers (Pancreatic, Endometrial, Gastric, GBM, etc.) – Ongoing Clinical Trials 49

# List Of Tables in Poly(adenosine diphosphate [ADP]-ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-0-2017]

Table 1a PARP Inhibitors: Drugs – Approved and in the Pipeline for Solid Tumors 9-10

Table 1b Comparative in vitro and Other Preclinical Properties of Select PARP Inhibitors 10

Table 2 Comparative Clinical Efficacy and Safety data of Approved PARP inhibitors in Recurrent Advanced Ovarian Cancer 16-18

Table 3 Future Market Potential of PARP inhibitors 27

Table 4 Historical M&A and Licensing Deals for PARP inhibitors 30

## Appendix

I Ovarian Cancer – Ongoing Clinical Trials 33-39

II Breast Cancer – Ongoing Clinical Trials 40-44

III Prostate Cancer – Ongoing Clinical Trials 45-46

IV Lung Cancer – Ongoing Clinical Trials 47-48

V Other Cancers (Pancreatic, Endometrial, Gastric, GBM etc.) – Ongoing Clinical Trials 49-56

# List Of Figures, Charts and Diagrams in Poly(adenosine diphosphate [ADP]-ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-07-2017]

Figure 1A: DNA Repair Pathways 7

Figure 1B: PARP Inhibitors Drive Synthetic Lethality 7

Figure 2: Rationale for targeting BRCA and Other Mutations by PARP in Solid Tumors 12

Figure 3: Better Therapies for Ovarian Cancer in the Next Five Years 19

Figure 4: Leading sites of Cancer Cases and Deaths – 2017 Estimates: US 28

Figure 5: Leading sites of Cancer Cases and Deaths Estimates: Worldwide 29

# How to Buy...

Poly(adenosine diphosphate [ADP]-ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors - Current and Future Potential [Report Updated: 28-07-2017]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/107360>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$3200** | Single User Price
- \$4200** | Site License Price
- \$6000** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.